Drug
Tgd001
Tgd001: highest development phase Phase 1/2, developed by TargED Biopharmaceuticals B.V.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- TargED Biopharmaceuticals B.V.
Trials
| Drug | Phase | Indication |
|---|---|---|
| TGD001 NCT07459114 | Phase 1/2 | Thrombotic Microangiopathies |
Latest
No recent events.
Follow Tgd001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.